U.S. markets open in 7 hours 58 minutes
  • S&P Futures

    3,975.25
    +9.50 (+0.24%)
     
  • Dow Futures

    33,848.00
    +45.00 (+0.13%)
     
  • Nasdaq Futures

    11,686.50
    +41.00 (+0.35%)
     
  • Russell 2000 Futures

    1,822.30
    +2.60 (+0.14%)
     
  • Crude Oil

    71.91
    +0.45 (+0.63%)
     
  • Gold

    1,808.30
    +6.80 (+0.38%)
     
  • Silver

    23.42
    +0.18 (+0.77%)
     
  • EUR/USD

    1.0574
    +0.0015 (+0.14%)
     
  • 10-Yr Bond

    3.4910
    0.0000 (0.00%)
     
  • Vix

    22.29
    -0.39 (-1.72%)
     
  • GBP/USD

    1.2261
    +0.0024 (+0.19%)
     
  • USD/JPY

    136.1120
    -0.5180 (-0.38%)
     
  • BTC-USD

    17,210.93
    +400.49 (+2.38%)
     
  • CMC Crypto 200

    405.82
    +11.13 (+2.82%)
     
  • FTSE 100

    7,472.17
    -17.02 (-0.23%)
     
  • Nikkei 225

    27,901.01
    +326.58 (+1.18%)
     

Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Lumos Pharma, Inc.
Lumos Pharma, Inc.

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.

Event:

 

H.C. Wainwright 24th Annual Global Investment Conference – September 12th-14th

Presentation:

 

Pre-recorded presentation available beginning September 12th at 7:00 AM (EDT)

Webcast link:

 

Here

1x1 Meetings:

 

Management will be available for one-on-one meetings during the conference, September 12th-14th

The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.